The American labor market is experiencing a fascinating dichotomy as it navigates late 2024 and 2025. While overall job creation has shown signs of moderation and significant revisions to earlier optimistic figures, a robust undercurrent of growth is emerging from the nation's manufacturing sector. This resurgence, largely driven by substantial
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market.
But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
The Dow Jones Industrial Average has been on a roller-coaster ride in November 2025, experiencing significant volatility and sending mixed signals across various sectors. While the index achieved a fresh all-time high earlier in the month, it has since grappled with an "indiscriminating sell-off" fueled by concerns over an "AI
The Dow Jones Industrial Average (DJIA) has recently been a barometer of a market caught between conflicting forces, demonstrating significant daily fluctuations throughout November 2025. While the venerable index has managed to maintain positive year-to-date performance, its recent movements underscore a pervasive sentiment of uncertainty, where optimism for potential interest
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with BioMarin Pharmaceutical (NASDAQ:BMRN).
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.
Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New York, extending its month-to-date slide to more than 5%.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an uncertain economic landscape. While specific real-time data for this future date is beyond current predictive capabilities, an analysis of the sector's
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance, particularly by companies at the forefront of artificial intelligence (AI), tech stocks are now experiencing a noticeable downturn. This
